Filing Details
- Accession Number:
- 0001209191-21-064884
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-16 19:12:00
- Reporting Period:
- 2021-11-12
- Accepted Time:
- 2021-11-16 19:12:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1287098 | Maxcyte Inc. | MXCT | Services-Commercial Physical & Biological Research (8731) | 522210438 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1875169 | Louise Amanda Murphy | C/O Maxcyte, Inc. 22 Firstfield Road, Suite 110 Gaithersburg MD 20878 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-12 | 51,103 | $4.42 | 51,103 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-12 | 51,103 | $12.66 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-11-15 | 61,591 | $4.42 | 61,591 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-15 | 61,591 | $12.16 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-11-16 | 37,306 | $4.42 | 37,306 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-16 | 37,306 | $12.08 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-11-12 | 51,103 | $0.00 | 51,103 | $4.42 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-11-15 | 61,591 | $0.00 | 61,591 | $4.42 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-11-16 | 37,306 | $0.00 | 37,306 | $4.42 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 1,098,897 | 2030-09-08 | No | 4 | M | Direct | |
| 1,037,306 | 2030-09-08 | No | 4 | M | Direct | |
| 1,000,000 | 2030-09-08 | No | 4 | M | Direct |
Footnotes
- This exercise price is in U.S. Dollars and reflects the conversion of GBP to USD at an exchange rate of GBP 1.00 to $1.34.
- The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.56 to $12.765, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.03 to $12.615, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- One-sixteenth (1/16th) of the shares underlying this option vested on December 7, 2020, and the remainder vested or shall vest monthly in forty-five (45) equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Billionaire Hedge Funds
